Twist Bioscience Corp TWST Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$120.79 up $0.18, 0.15% at close Nov 6
Last close · Previous close $120.61
- Market cap
- $7.52BAt the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$2.22Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$120.79up $0.18, 0.15%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$120.61Nov 5
- Volume2.06MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume2.41MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $23.30 to $219.71; now $120.79
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
TWST beat the S&P 500 in 4 of 6 periods.
| Period | TWST and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | TWST: down 27.7% S&P 500: down 5.6% | TWST trailed the S&P 500 by 22.1 percentage points Trailed |
| 3M | TWST: up 10.7% S&P 500: down 4.1% | TWST beat the S&P 500 by 14.8 percentage points Beat |
| YTD | TWST: up 280.8% S&P 500: up 8.7% | TWST beat the S&P 500 by 272.1 percentage points Beat |
| 1Y | TWST: up 294.4% S&P 500: up 10.9% | TWST beat the S&P 500 by 283.5 percentage points Beat |
| Long term | ||
| 3Y | TWST: up 581.7% S&P 500: up 75.0% +89.6% vs +20.5% a year | TWST beat the S&P 500 by 506.7 percentage points Beat |
| 5Y | TWST: down 11.1% S&P 500: up 67.8% −2.3% vs +10.9% a year | TWST trailed the S&P 500 by 78.9 percentage points Trailed |
$10,000 invested in TWST 5 years ago (Nov 5, 2021) would be worth about $8,889 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
TWST beat the S&P 500 in 4 of 6 periods.
| Period | TWST and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | TWST: down 27.7% S&P 500: down 5.6% | TWST trailed the S&P 500 by 22.1 percentage points Trailed |
| 3M | TWST: up 10.7% S&P 500: down 4.3% | TWST beat the S&P 500 by 15.0 percentage points Beat |
| YTD | TWST: up 280.8% S&P 500: up 7.8% | TWST beat the S&P 500 by 273.0 percentage points Beat |
| 1Y | TWST: up 294.4% S&P 500: up 9.7% | TWST beat the S&P 500 by 284.7 percentage points Beat |
| Long term | ||
| 3Y | TWST: up 581.7% S&P 500: up 68.8% +89.6% vs +19.1% a year | TWST beat the S&P 500 by 512.9 percentage points Beat |
| 5Y | TWST: down 11.1% S&P 500: up 56.9% −2.3% vs +9.4% a year | TWST trailed the S&P 500 by 68.0 percentage points Trailed |
$10,000 invested in TWST 5 years ago (Nov 5, 2021) would be worth about $8,889 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$207.97
Closing high on . Now 41.9% below that record.
Split-adjusted daily closes since Oct 31, 2018.
Stock splits
TWST hasn’t split since its price history begins in 2018.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
n/mDiluted EPS of −$2.22 over the last 12 months
A P/E ratio isn’t meaningful while earnings over the last 12 months are negative. How to read P/E
Other valuation measures
- 17.4×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 16.9×Book value as of Jun 30, 2026
Price relative to accounting equity (book value) per share on the Jun 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - −1.24%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $7.46BAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own TWST DCF in Excel. Value Twist Bioscience with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $431.80Mup 19.2%
- Net income
- −$136.72M
- Diluted EPS
- −$2.22
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Sep 30, 2024) | $84.71M | −$34.66M | −$0.59 |
| Q1 FY25 (Dec 31, 2024) | $88.71M | −$31.59M | −$0.53 |
| Q2 FY25 (Mar 31, 2025) | $92.79M | −$39.33M | −$0.66 |
| Q3 FY25 (Jun 30, 2025) | $96.06M | $20.39M | $0.33 |
| Q4 FY25 (Sep 30, 2025) | $99.01M | −$27.14M | −$0.45 |
| Q1 FY26 (Dec 31, 2025) | $103.70M | −$30.51M | −$0.50 |
| Q2 FY26 (Mar 31, 2026) | $110.72M | −$44.02M | −$0.71 |
| Q3 FY26 (Jun 30, 2026) | $118.38M | −$35.05M | −$0.56 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Sep 30, 2021) | $132.33M | −$152.10M | −$3.15 |
| FY22 (Sep 30, 2022) | $203.57M | −$217.86M | −$4.04 |
| FY23 (Sep 30, 2023) | $245.11M | −$204.62M | −$3.60 |
| FY24 (Sep 30, 2024) | $312.97M | −$208.73M | −$3.60 |
| FY25 (Sep 30, 2025) | $376.57M | −$77.67M | −$1.30 |
Margins
- Gross 52.0%
- Operating −33.6%
- Net −31.7%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$93.22MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$53.07MLast 12 months
- Capital spending$40.15MLast 12 months
- −21.6%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $13.82MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $237.06MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$108.59MAs of Jun 30, 2026
- Net cash$128.47MAs of Jun 30, 2026
- 2.67As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.24As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 3 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- −29.9%Last 12 months
Over the last 12 months, Twist Bioscience lost money: its net loss was 29.9% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −20.8%Last 12 months
Over the last 12 months, Twist Bioscience’s net loss was 20.8% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Twist Bioscience Corp
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
TWST news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
TWST stock FAQ
What is TWST stock’s price today?
Twist Bioscience (TWST) traded at $120.79 at the close on , up $0.18 (0.15%) from the previous close of $120.61. Over the past 52 weeks it has traded between $23.30 and $219.71.
If you invested $1,000 in TWST 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in TWST on would be worth about $889 at the close on , a total return of −11.1%. The same $1,000 would be worth $3,944 if invested one year ago. Past performance doesn’t predict future returns.
What is Twist Bioscience’s market cap?
Twist Bioscience’s market capitalization is about $7.5 billion. That’s Tiingo’s daily market cap for , at that day’s closing price of $120.79 (how market cap works). Twist Bioscience reported 62.27M shares outstanding at the end of its latest quarter ().
What is TWST’s P/E ratio?
TWST’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$2.22).
How much revenue does Twist Bioscience make?
Twist Bioscience reported $431.8 million of revenue over the four quarters to , up 19.2% from the twelve months before. In its latest quarter (Q3 FY26, ended ) revenue was $118.4 million, up 23.2% from a year earlier.
Is Twist Bioscience profitable?
Not over the four quarters to . Twist Bioscience reported a net loss of $136.7 million across those four quarters on $431.8 million of revenue.
What are TWST’s earnings per share?
TWST’s diluted earnings per share were −$2.22 over the four quarters to , compared with −$1.45 in the twelve months before. The latest quarter (Q3 FY26) brought −$0.56 per share, against $0.33 a year earlier (how EPS works).
Does TWST pay a dividend?
Twist Bioscience hasn’t paid a dividend in the last twelve months.
What is TWST’s 52-week high and low?
Over the past 52 weeks TWST has traded as low as $23.30 and as high as $219.71. At $120.79 at the close on , it is 45.0% below that high and 418.4% above the low.
What is TWST’s all-time high?
TWST’s highest closing price was $207.97 on , adjusted for stock splits. At $120.79 at the close on , it is 41.9% below that record.
Has TWST stock ever split?
No. TWST hasn’t split since its price history begins in 2018.
How has TWST stock performed?
Including dividends and measured to the close on , TWST has returned +280.8% so far this year and +294.4% over the past year, and −11.1% over five years (−2.3% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Twist Bioscience in?
Twist Bioscience is in the Healthcare sector and the Diagnostics & Research industry, and is headquartered in California, USA.
What exchange does TWST trade on?
Twist Bioscience trades on the Nasdaq under the ticker symbol TWST. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.